Skip to main content

Table 1 Baseline characteristics

From: Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis

Parameters All patients
n = 178
Nintedanib
n = 62
Pirfenidone
n = 80
No treatment
n = 36
p-value
Age, mean (SD) 73.80 (7.53) 72.16 (7.15) 73.66 (6.87) 76.92 (8.74) 0.0097
Men, n (%) 136 (76.4%) 47 (75.8%) 62 (77.5%) 27 (75.0%) 0.95
BMI, mean (SD) 27.31 (4.51) 27.62 (4.62) 27.57 (4.16) 26.16 (5.02) 0.224
FVC (L), mean (SD) 3.04 (0.86) 3.05 (0.91) 3.08 (0.83) 2.94 (0.88) 0.7
FVC (% pred), mean (SD) 89.51 (19.52) 88.48 (19.57) 90.09 (18.71) 90.00 (21.65) 0.878
DLCO (% pred), mean (SD) 52.85 (13.25) 53.81 (12.68) 52.63 (13.13) 51.58 (14.8) 0.725
Change in FVC% pred. from baseline to 12 months, mean (SD) 0.13 (10.16) 0.20 (9.92) 0.06 (10.44) 0.15 (10.41) 0.997
Change in DLCO% pred. from baseline to 12 months, mean (SD) − 5.03 (7.98) − 4.70 (6.83) − 5.37 (9.10) − 4.85 (7.34) 0.9
6MWT (meters), mean (SD) 442.61 (105.58) 475.92 (95.2) 436.09 (106.85) 390.97 (101.61) 0.0009
Smoking status, n (%)
Never 46 (25.8%) 10 (16.1%) 25 (31.2%) 11 (30.6%) 0.039
Active 11 (6.2%) 1 (1.6%) 6 (7.5%) 4 (11.1%)
Former 121 (68.0%) 51 (82.3%) 49 (61.2%) 21 (58.3%)
GAP index, n (%)
I 88 (49.7%) 34 (54.8%) 36 (45.0%) 18 (51.4%) 0.08
II 82 (46.3%) 27 (43.5%) 42 (52.5%) 13 (37.1%)
III 7 (4.0%) 1 (1.6%) 2 (2.5%) 4 (11.4%)
Progression at 12 months, n (%) 84 (47.2%) 27 (43.5%) 38 (47.5%) 19 (52.8%) 0.67